What does the evidence say about Soy Isoflavones Bone Markers Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Soy Isoflavones Bone Markers Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - The high prevalence of osteoporosis and the increased fracture risk among the old and middle-aged can be seen due to rapid and continuous bone resorption, as opposed to growth time when bone formation surpasses bone resorption. [Hooshiar Saeedeh Hosseini (2022); evidence level 3] - Osteoporosis is specified by the deterioration of bone tissue microarchitecture and reduction of bone mass, which causes an enhanced risk of fracture and fragility of bone []. [Hooshiar Saeedeh Hosseini (2022); evidence level 3] - Skeletal and extra-skeletal risk factors and age are related to osteoporotic fractures incidence [–]. [Hooshiar Saeedeh Hosseini (2022); evidence level 3] - 1 2 3 4 6 4 5 7 8 9 10 12 13 14 12 15 Bone, as active tissue, continuously remodels throughout life []. [Hooshiar Saeedeh Hosseini (2022); evidence level 3] - Results The combined EUE and Isf treatment significantly improved biomechanical performance of the femur and restored bone mineral content in ovariectomized rats. [Zhao R (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.